Charlotte Niemeyer

Title: Charlotte Niemeyer: Innovator in Cancer Diagnostics and Therapeutics

Introduction

Charlotte Niemeyer is a prominent inventor based in Freiburg, Germany. She has made significant contributions to the field of cancer research, particularly in the area of diagnostic and therapeutic applications related to specific genetic mutations.

Latest Patents

Charlotte Niemeyer holds a patent for her work on PTPN11 (SHP-2) mutations and cancer. This patent describes diagnostic and therapeutic applications for certain types of cancer and precancerous conditions, especially those associated with hematologic cells. The focus of her research is on cancers linked to increased signaling in the RAS-MAP kinase pathway. The applications outlined in her patent are based on specific mutations in the protein tyrosine phosphatase gene PTPN11, which promote a gain-of-function in PTPN11 activity. Additionally, her patent includes nucleotide sequences, amino acid sequences, probes, and primers related to PTPN11 and its variants, as well as cells expressing these variants.

Career Highlights

Charlotte Niemeyer is affiliated with the Icahn School of Medicine at Mount Sinai, where she continues her research and innovation in cancer diagnostics. Her work has garnered attention for its potential impact on the treatment and understanding of various cancers.

Collaborations

Some of her notable collaborators include Bruce D Gelb and Marco Tartaglia, who have contributed to her research endeavors.

Conclusion

Charlotte Niemeyer is a trailblazer in the field of cancer research, with her innovative work on PTPN11 mutations paving the way for advancements in diagnostic and therapeutic applications. Her contributions are vital to the ongoing fight against cancer.